Ube Corporation · TSE:4208
Ube — Ube Industries — Q3 FY2015 Earnings Presentation
19 slides from Ube's earnings presentation, Feb 2, 2016
Slide 1: Financial Results for the 3rd Quarter FY 2015
1 Financial Results for the 3rd Quarter FY 2015 February 2, 2016 ※This”3rd Quarter(3Q)” date states information for 9 month total.
Slide 2: Scope of Consolidation
2 Scope of Consolidation - Financial Results for the 3rd Quarter FY2015 - End of FY2014 End of FY2015 3Q Change Item Notes (A) (B) （B) - （A) + Sanshin Tsusho Co., Ltd. Number of － Advanced Electrolyte consolidated 71 70 -1 Technologies (USA) LLC subsidiaries － Advanced Electrolyte Technologies (Euro
Slide 3: Environmental Factors
3 Environmental Factors - Financial Results for the 3rd Quarter FY2015 - （Billion Yen） Impacts on FY2014 3Q FY2015 3Q Change Item Consolidated (A) (B) (B) - (A) OP Income Exchange Rate Yen/$ 106.9 121.7 14.8 1.3 (CIF) $/ｔ 913 517 -396 7.1 Naphtha (Domestic) Yen/KL 68,400 45,700 -22,700 (5.8) Materia
Slide 4: Major P/L & B/S Items
4 Major P/L ＆ B/S Items - Financial Results for the 3rd Quarter FY2015 - (Billion Yen) FY2014 3Q FY2015 3Q Change Item (A) (B) (B) - (A) Sales 473.7 482.3 8.5 Operating income 14.3 31.2 16.9 Ordinary income 13.9 30.1 16.2 Profit attributable to owners of parent 5.1 19.2 14.0 End of FY2014 End of FY2
Slide 5: Sales by Segment
5 Sales by Segment - Financial Results for the 3rd Quarter FY2015 - （Billion Yen） FY2014 3Q FY2015 3Q Change Segment Major Factors (A) (B) (B) - (A) Nylon/Caprolactam chain △7.2, Synthetic rubber △1.2, Chemicals 207.5 203.2 -4.3 Battery Materials and Fine Chemicals 4.3, Polyimide and Specialty Produ
Slide 6: Operating Income by Segment
6 Operating Income by Segment - Financial Results for the 3rd Quarter FY2015 - （Billion Yen） FY2014 3Q FY2015 3Q Change Segment Major Factors (A) (B) (B) - (A) Nylon/Caprolactam chain 9.0, Synthetic rubber 0.6, Chemicals -3.4 9.5 13.0 Battery Materials and Fine Chemicals 1.5, Polyimide and Specialty
Slide 7: Analysis of Operating Income
7 Analysis of Operating Income - Financial Results for the 3rd Quarter FY2015 - （Billion Yen） Operating Income Segment FY2014 3Q FY2015 3Q Change Sales Fixed Price Others Volume Cost (A) (B) (B) - (A) *1 *2 Chemicals -3.4 9.5 13.0 8.7 4.4 0.7 -0.7 Pharmaceutical 1.0 0.5 -0.5 -0.0 -1.0 -0.0 0.5 Cemen
Slide 8: Non Operating Items
8 Non Operating Items - Financial Results for the 3rd Quarter FY2015 - （Billion Yen） FY2014 3Q FY2015 3Q Change Item (A) (B) (B) - (A) Operating income 14.3 31.2 16.9 Net interest expense -0.9 -0.8 0.1 Non operating income Equity in earnings of unconsolidated subsidiaries 0.9 2.5 1.6 and affiliated
Slide 9: Extraordinary Items
9 Extraordinary Items - Financial Results for the 3rd Quarter FY2015 - （Billion Yen） FY2014 3Q FY2015 3Q Change Item (A) (B) (B) - (A) Gain on disposal of PP&E 0.5 0.3 -0.2 Reversal of accrued expenses from business withdrawal - 1.5 1.5 Loss on disposal of PP&E ＊1 -1.9 -4.2 -2.2 Loss on impairment ＊
Slide 10: Operating Income - Net Income
10 Operating Income - Net Income - Financial Results for the 3rd Quarter FY2015 - （Billion Yen） FY2014 3Q FY2015 3Q Change Item (A) (B) (B) - (A) Operating income 14.3 31.2 16.9 Non operating item -0.4 -1.1 -0.6 Ordinary income 13.9 30.1 16.2 Extraordinary item -6.4 -3.2 3.2 Income before income tax
Slide 11: Consolidated Balance Sheet
11 Consolidated Balance Sheet - Financial Results for the 3rd Quarter FY2015 - （Billion Yen） End of FY2014 End of FY2015 3Q Change Item (A) (B) (B) - (A) Current assets 282.8 288.0 5.2 Fixed assets 428.5 417.6 -10.8 Total assets 711.5 705.8 -5.6 Interest-bearing debts 239.7 227.2 -12.4 Other liabili
Slide 12: Consolidated Statements of Cash Flows
12 Consolidated Statements of Cash Flows - Financial Results for the 3rd Quarter FY2015 - （Billion Yen） Item FY2014 3Q FY2015 3Q Income before income tax and minority interests 26.8, Depreciation and amortization 26.5, A.Cash flows from operating activities 25.7 35.9 Workig capital -10.1, Payment of
Slide 13: Appendix
13 Appendix UBE
Slide 14: Reference: Major P/L & B/S Items - FY2015 Consolidated Forecasts
14 【Reference】 Major P/L ＆ B/S Items - FY2015 Consolidated Forecasts - （Billion Yen） FY2014 (A) FY2015 (B) Change (B) - (A) Item 3Q 3Q (B) 3Q (Progress) (Progress) 473.7 482.3 Sales 641.7 670.0 28.3 8.5 (73.8%) (72.0%) 14.3 31.2 Operating income 24.1 39.0 14.9 16.9 (59.4%) (80.0%) 13.9 30.1 Ordinary
Slide 15: Reference: FY2015 Changes in results - Sales by Segment
15 【Reference】 FY2015 Changes in results - Sales by Segment - (Billion Yen) FY2015 Full-year Progress Segment 1Q 2Q 3Q 4Q Total Forecast % Chemicals 70.0 66.9 66.2 - 203.2 287.0 70.8% Pharmaceutical 1.7 1.4 2.4 - 5.7 9.5 60.1% Cement & 58.9 59.3 61.6 - 179.8 240.0 75.0% Construction Materials Machin
Slide 16: Reference: FY2015 Changes in results - Operating Income by Segment
16 【Reference】 FY2015 Changes in results - Operating Income by Segment - (Billion Yen) FY2015 Full-year Progress Segment 1Q 2Q 3Q 4Q Total Forecast % Chemicals 3.5 2.8 3.1 - 9.5 11.0 87.1% Pharmaceutical -0.0 0.2 0.3 - 0.5 1.2 45.5% Cement & 4.2 5.5 5.9 - 15.7 19.0 83.2% Construction Materials Machi
Slide 17: Reference: Major data
17 【Reference】 Major data - Financial Results for the 3rd Quarter FY2015 - (Billion Yen) FY2015 full-year Item FY2014 3Q FY2015 3Q FY2014 full-year Forecast Capital investment 30.4 21.0 38.0 42.5 Depreciation andamortization 24.6 26.5 36.5 33.5 R&D expense 10.3 9.9 14.0 13.8 Adjusted operating profi
Slide 18: Reference: Major Subsidiaries
18 【Reference】 Major Subsidiaries - Financial Results for the 3rd Quarter FY2015 - (Billion Yen) Operating Sales income Subsidiaries and Affiliates Business change from FY2015 3Q FY2014 3Q UBE CHEMICALS (ASIA) PUBLIC CO., LTD Manufacture and sales of caprolactam and polyamide resin 31.4 ↑ Manufactur
Slide 19: Forward-looking statements disclaimer
19 This presentation material contains forward-looking statements concerning UBE’s future plans, strategies, and performance. These forward-looking statements are not historical facts; rather, they represent assumptions and beliefs based on economic, financial, and competitive date currently availab